Table 3 Stratified analyses between rs12700386 polymorphism and the risk of osteoarthritis

 Male

1.42 (0.89–2.25); 0.156

1.80 (0.70–4.64); 0.238

1.62 (0.63–4.12); 0.351

1.47 (0.95–2.28); 0.094

 Female

1.31 (0.87–1.97); 0.214

2.24 (0.89–5.61);0.107

1.99 (0.81–4.91); 0.176

1.39 (0.94–2.06); 0.110

 Yes

1.29 (0.57–2.94); 0.674

2.51 (1.09–5.78); 0.029

2.67 (1.15–6.18); 0.025

2.01 (1.08–3.76); 0.029

 No

1.35 (0.95–1.91); 0.111

0.97 (0.30–3.13); 0.602

0.84 (0.26–2.69); 0.504

1.33 (0.94–1.87); 0.116

 Yes

1.15 (0.68–1.94); 0.687

2.93 (1.06–8.08); 0.049

2.80 (1.03–7.59); 0.054

1.35 (0.83–2.21); 0.259

 No

1.44 (0.99–2.09); 0.058

1.47 (0.61–3.57); 0.495

1.25 (0.89–1.76); 0.222

1.45 (1.00–2.07); 0.053

  < 55

1.09 (0.60–2.00); 0.878

2.19 (0.65–7.35); 0.236

2.07 (0.65–6.58); 0.254

1.18 (0.65–2.13); 0.653

  ≥ 55

1.55 (1.07–2.25); 0.023

1.95 (0.88–4.30); 0.110

1.71 (0.78–3.74); 0.235

1.61 (1.13–2.28); 0.009

  < 25

1.38 (0.89–2.13);0.153

1.49 (0.53–4.14);0.605

1.51 (0.55–4.13);0.453

1.01 (0.67–1.54);0.518

  ≥ 25

1.83 (1.19–2.81);0.007

2.54 (1.07–6.04);0.049

2.05 (0.88–4.80);0.138

1.92 (1.28–2.89);0.002